CYTK Q1 2021 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+71.2% YoY

Gross Profit

-$25M-382.0% margin

Operating Income

-$41M-620.2% margin

Net Income

-$47M-719.4% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

-2.6%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$36M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$577M

Total Liabilities

$509M

Stockholders' Equity

$68M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$4M	+71.2%
Gross Profit	-$25M	-$18M	-39.6%
Operating Income	-$41M	-$30M	-33.8%
Net Income	-$47M	-$39M	-19.5%

Revenue Segments

Research And Development

$7M58%

Research And Development Milestone Grant And Other Revenues Net

$5M42%